“Established companies and new ones work together, the academic community gets involved, and value is also added by the state’s comprehensive vendor network, and a strong manufacturing base," said Dean J. Paranicas, CEO of the HealthCare Institute of New Jersey. "The topping is the state’s position as a transportation hub, easy access to capital markets, and a diverse population. I’m excited about the future.”

There’s no question that life science, biotech and related companies have made significant advances in combating life-threatening illnesses and other conditions. But the industry in general appears to be falling short when it comes to recruiting and advancing women and other minorities, according to some government statistics.

Life science and biopharma companies have brought about significant changes in the approach to medicine, with innovative concepts like gene-based individualized treatments that have helped to shake the foundation of the healing arts. But some industry experts say that in 2019, the companies behind these kinds of advances will also have to contend with change on a different front: their business approach.

According to a study published in the journal Intensive Care Medicine, patients in emergency departments who experience life-threatening medical conditions, and are surrounded by compassionate health care personnel are less likely to develop post-traumatic stress disorder.

Dr. Carlos Benito's relationship with Saint Peter’s dates back more than 25 years to his residency and fellowship training, which he completed there.

A panel of medical and social service experts and clergy addressed misconceptions associated with organ donation and transplantation - like the one about not getting treated to survive if you're signed up to be a donor - at University Hospital in Newark during a discussion presented by NJ Sharing Network.

The congressman's office said the letter comes in the wake of several of these avoidable tragedies, including one affecting a family in his home state of New Jersey.

Six organizations will receive the funding from the New Jersey Department of Labor and Workforce Development to provide training and support to individuals whose work has been interrupted due to the opioid epidemic under The Opioid Recovery Employment Program, or Pathways to Recovery.

The biopharmaceutical company said the previously announced sale was brokered through the state Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for New Jersey’s 2018 Fiscal Year.

“This unique transaction is part of our strategy to transform drug development, strengthening Covance’s ability to offer comprehensive global nonclinical research services to the biopharma industry,” said LabCorp Chairman and CEO David King.

The Princeton-based drug development, regulatory science, evidence and market access services company announced the senior executive appointments for its Simcyp division.